Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.63 |
| ▸ | F10 | P00742 | 12/20 | 0.45 |
| ▸ | F2 | P00734 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5531631 | 0.94 | KCNH2 (0.54) | KCNH2F10F2MEN1NPC1 | |
| SCHEMBL5529598 | 0.92 | KCNH2 (0.58) | KCNH2F10F2 | |
| SCHEMBL5537345 | 0.92 | KCNH2 (0.51) | KCNH2F10F2MEN1NPC1 | |
| SCHEMBL5533838 | 0.91 | KCNH2 (0.51) | KCNH2F10F2MEN1NPC1 | |
| SCHEMBL5535968 | 0.89 | F10 (0.55) | KCNH2F10KMT2A | |
| SCHEMBL5534017 | 0.86 | KCNH2 (0.49) | KCNH2F10F2NPC1RAB9A | |
| SCHEMBL5532886 | 0.85 | KCNH2 (0.53) | KCNH2F10F2KMT2A | |
| SCHEMBL5532890 | 0.85 | KCNH2 (0.53) | KCNH2F10F2KMT2A | |
| SCHEMBL14345306 | 0.85 | KCNH2 (0.86) | KCNH2F10F2 | |
| SCHEMBL5528366 | 0.85 | F10 (0.55) | KCNH2F10KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373194-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | claimed |
| WO-2002079145-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | claimed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1373194-B1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | SERPINC1, TFPI, F12 | KCNH2 1203/4885F10 10/4885F2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.